JonesTrading analyst Soumit Roy maintained a Hold rating on Inhibikase Therapeutics (IKT – Research Report) today. The company’s shares closed today at $0.57.
Roy covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Monopar Therapeutics Inc, and Anavex Life Sciences. According to TipRanks, Roy has an average return of -1.8% and a 27.74% success rate on recommended stocks.
Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $5.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.21 and a one-year low of $0.44. Currently, Inhibikase Therapeutics has an average volume of 316.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.
Read More on IKT:
- Inhibikase Therapeutics provides update on Parkinson’s trials
- Inhibikase Therapeutics initiated with a Buy at H.C. Wainwright
- Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
- Inhibikase Therapeutics provides interim update from study of IkT-001Pro
